Application of targeted high-throughput sequencing as a diagnostic tool for neonatal genetic metabolic diseases following tandem mass spectrometry screening
Frontiers in Public Health · 2024
DOI: 10.3389/fpubh.2024.1461141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2024. Verfasst von Guihua Lai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Ganzhou Maternal and Child Health Hospital, Ganzhou, Jiangxi, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, High-Throughput Nucleotide Sequencing, Neonatal Screening. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tandem mass spectrometry (MS/MS) is a crucial technique for detecting inborn errors of metabolism (IEM) in newborns. However, the high false positive rate poses challenges in diagnosing specific types of diseases. Therefore, this study aimed to evaluate the role of targeted next-generation sequencing (NGS) in the accurate diagnosis of positive samples identified through MS/MS screening.
Methods
A cohort study of 260,915 newborns was conducted from January 2018 to June 2023 in Ganzhou City, southern China. Heel blood samples were collected within 72 h of birth and subjected to MS/MS analysis. Infants with positive MS/MS results underwent targeted NGS to confirm the diagnosis and identify genetic variants.
Results
Among 1,265 suspected cases with positive MS/MS results, 73 were confirmed by NGS, and 12 were identified as carriers of recessive diseases. The overall incidence rate was 1 in 3,574, effectively ruling out 94.2% (1,192/1,265) of the MS/MS false-positive. We found 76 variants in 18 genes associated with 15 types of IEM. Among these, 64.47% (49/76) were pathogenic, 10.53% (8/76) were likely pathogenic. Remarkably, 7.89% (6/76) were identified as novel variants. Variants in SLC22A5 (NM_003060.4) gene was most prevalent, accounting for 41% (77/188), with hotspot variants including c.51C > G, c.1400C > G, and c.338G > A.
Conclusion
Targeted NGS technology can serve as a crucial diagnostic tool for neonatal genetic metabolic diseases following MS/MS screening. Additionally, we identified IEM variant hotspots and some novel variants in our region, which are the underlying causes of disease in patients with IEM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Laboratory, Ganzhou Maternal and Child Health Hospital, Ganzhou, Jiangxi, China.
Zitieren
APA
Lai, G., Gu, Q., Lai, Z., Chen, H., Tu, X., Chen, J., & Huang, J. (2024). Application of targeted high-throughput sequencing as a diagnostic tool for neonatal genetic metabolic diseases following tandem mass spectrometry screening. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1461141
Vancouver
Lai G, Gu Q, Lai Z, Chen H, Tu X, Chen J, et al. Application of targeted high-throughput sequencing as a diagnostic tool for neonatal genetic metabolic diseases following tandem mass spectrometry screening. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1461141
BibTeX
@article{Lai2024,
author = {Lai, Guihua and Gu, Qiying and Lai, Zhiyong and Chen, Haijun and Tu, Xiangwen and Chen, Junkun and Huang, Jungao},
title = {Application of targeted high-throughput sequencing as a diagnostic tool for neonatal genetic metabolic diseases following tandem mass spectrometry screening},
journal = {Frontiers in Public Health},
year = {2024},
doi = {10.3389/fpubh.2024.1461141}
}
EUVIMED